TABLE 3.
Descriptive Analyses of Adherence to and Duration of Treatment with Erlotinib
| Measure | Erlotinib Cohort n = 1,452 | First-Line Erlotinib n = 551 | Second-Line Erlotinib n = 901 |
Erlotinib Cohort
with Chart Data n = 729 |
|---|---|---|---|---|
| 2 or more erlotinib claimsa, n (%) | 1,088 (74.9) | 407 (73.9) | 681 (75.6) | 572 (78.5) |
| MPR, mean (± SD) | 0.97 (± 0.16) | 0.96 (± 0.17) | 0.98 (± 0.16) | 0.97 (± 0.16) |
| Median, interquartile range Q1-Q3 | 1.01, 0.93-1.06 | 1.00, 0.92-1.05 | 1.01, 0.93-1.07 | 1.01, 0.94-1.06 |
| Min., max. | 0.04, 1.90 | 0.04, 1.55 | 0.18, 1.90 | 0.04, 1.90 |
| % Nonadherent (MPR ≤ 80%)b, n (%) | 136 (12.5) | 58 (14.3) | 78 (11.5) | 77 (13.5) |
| Gap days in therapy, mean (± SD) | 36.1 (± 114.3) | 47.0 (± 146.0) | 29.6 (± 89.7) | 36.2 (± 112.9) |
| Median, interquartile range Q1-Q3 | 5, 0-26 | 8, 0-38 | 5, 0-21 | 6, 0-29 |
| Min., max. | 0, 2,131 | 0, 2,131 | 0, 1205 | 0, 2,131 |
| Deceased during post-perioda, n (%) | 843 (77.5) | 304 (74.7) | 539 (79.1) | 438 (76.6) |
| Censored during post-perioda, n (%) | 184 (16.9) | 68 (16.7) | 116 (17.0) | 94 (16.4) |
| Persistence - days of therapy, mean (± SD) | 203.7 (±256.4) | 235.7 (±300.4) | 184.6 (±224.1) | 213.7 (±256.8) |
| Median, interquartile range Q1-Q3 | 109, 65-218 | 120, 67-255 | 96, 63-195 | 114, 65-251 |
| Min., max. | 8, 2,146 | 8, 2,146 | 27, 1,646 | 27, 2,146 |
| Discontinuation (60-day gap)a, n (%) | 73 (6.7) | 35 (8.6) | 38 (5.6) | 41 (7.2) |
aDenominator is total cohort.
bDenominator is the subgroup with 2 or more erlotinib claims.
max = maximum; min = minimum; MPR = medication possession ratio; SD = standard deviation; Q = quartile.